LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC

NCT06531902 | Completed

• 1 other identifier: REC #293
• Study Type: observational
• Target: 88
• Locations: 1 country
• Sites: 1

Brief Summary

The current study will compare the blood expression level of lncRNA NNT-AS1 and hsa-miR-485-5p, as well as heat shock protein 90 (HSP90) serum levels in both healthy and CRC Egyptian patients' cohort peripheral blood samples. Second, examine if lncRNA NNT-AS1/hsa-miR-485 5p/HSP90 axis, or individually investigated, would be used as a non-invasive molecular precision biomarker in liquid biopsy for better diagnostic utility for CRC patients. Also, based on CRC patients' group stratification by histologic grades 1-3. Finally, investigate the probable link/correlation between lncRNA NNT-AS1/hsa-miR-485-5p/HSP90 as an axis or individually in CRC Egyptian patients' cohort in relation to demographic data or clinicopathological characteristics. All findings will be confirmed or ruled out by in silico means as well.

Conditions

Colorectal Cancer

Keywords

Colorectal cancer; LncRNA NNT-AS1; Hsa-miR-485-5p; HSP90; Prognositic molecular biomarkers

Outcome Measures

Primary Outcomes (4)

• determination ofncRNA Expression pattern in CRC patients' in comparison to the control group

  9 months

• determination of HSP90 protein concentration in control and CRC cases

  12 months

• assigning Correlation coefficient between ncRNA, HSP90 protein, CEA, and CA19-9

  10 months

• carry out hsa-miR-485-5p target analysis

  3 months

Study Arms (2)

Patient group

A total of 60 CRC pateints' were enrolled in the study. CRC pateints' were treatment-naïve Egyptian patients' cohort admitted to the Clinical Oncology Clinic, National Cancer Institute (NCI), Cairo University, Cairo, Egypt. Male-to-female 1:1 (30/30) and their age range 24-76 years.

Healthy Control

28 age-matched and sex-matched apparently healthy volunteers, randomly selected from subjects enlisted during normal check-up examination or during blood donation. The control group participants were not taking any medication or suffering from any disease. Controls age range is 40-60 years and 13:15 male-to-female.

Eligibility Criteria

• Age: 24 Years - 76 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

3.1. Patients group A total of 60 CRC pateints' were enrolled in the study. CRC pateints' were treatment-naïve Egyptian patients' cohort admitted to the Clinical Oncology Clinic, National Cancer Institute (NCI), Cairo University, Cairo, Egypt. Male-to-female 1:1 (30/30) and their age range 24-76 years. 3.2. Control group 28 age-matched and sex-matched apparently healthy volunteers, randomly selected from subjects enlisted during normal check-up examination or during blood donation. The control group participants were not taking any medication or suffering from any disease. Controls age range is 40-60 years and 13:15 male-to-female.

You may qualify if:

• CRC diagnosed patients that is clinically confirmed by colonoscopy, abdominal radio-imaging, and histopathologicaly.

You may not qualify if:

• individuals receiving chemotherapy, radiation, or undergone surgery
• patients with blood disorders
• patients with any cancer other than CRC.
• Individuals with inadequate data or missing histopathological diagnoses
• distant metastases

Sponsors & Collaborators

• Ain Shams University: lead

Study Sites (1)

Faculty of Pharmacy, Ain Shams University, Advanced Biochemistry Research Lab

Cairo, 11566, Egypt

Location

Related Publications (1)

• El-Sheikh NM, Abulsoud AI, Fawzy A, Wasfey EF, Hamdy NM. LncRNA NNT-AS1/hsa-miR-485-5p/HSP90 axis in-silico and clinical prospect correlated-to histologic grades-based CRC stratification: A step toward ncRNA Precision. Pathol Res Pract. 2023 Jul;247:154570. doi: 10.1016/j.prp.2023.154570. Epub 2023 May 24.

  PMID: 37244051 RESULT

Related Links

• Publication

Biospecimen

Retention: SAMPLES WITH DNA

Five milliliters of peripheral venous blood liquid biopsy were collected from the antecubital vein from controls and CRC patients into clot activator polymer gel vacutainers (Greiner Bio-One GmbH, Australia). Vacutainers of completely coagulated samples were centrifuged at 4000 r.p.m for 10 min at room temperature (25 ◦C). The collected serum was aliquoted and kept at - 80 ◦C in three DNase/ RNase free Eppendorf tubes until analysis.

MeSH Terms

Conditions

Colorectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Study Officials

• Nadia Hamdy, PhD

  Faculty of pharmacy Ain Shams University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: professor of biochemistry and molecular biology

Study Record Dates

• First Submitted: May 16, 2024
• First Posted: August 1, 2024
• Study Start: October 1, 2020
• Primary Completion: March 1, 2021
• Study Completion: June 1, 2021
• Last Updated: August 1, 2024

Record last verified: 2024-07

Locations

EG (1)